A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Study ID
NCT07229729
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-A2102 — DRUG
    SHR-A2102.
  • Adebrelimab — DRUG
    Adebrelimab.
  • Paclitaxel — DRUG
    Paclitaxel.
  • Carboplatin — DRUG
    Carboplatin.
  • Alomnertinib Mesilate — DRUG
    Alomnertinib Mesilate.
  • Furmonertini Mesilate — DRUG
    Furmonertini Mesilate.
  • Osimertinib Mesylate — DRUG
    Osimertinib Mesylate.

Study Details

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Key Dates

Start date
Nov 24, 2025
Status verified
Nov 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2029

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-A2102 + Adebrelimab + Paclitaxel + Carboplatin Group
  • Active Comparator: SHR-A2102 + Alomnertinib/Osimertinib/Furmonertinib Group

Primary Outcome Measure

Pathology complete response (pCR) [ Time Frame: Up to approximately 20 weeks. ]

Central Contacts

Related Studies